Fatty acid metabolism in cystic fibrosis

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 83, Issue 3, 2010, Pages 121-129

  Strandvik, Birgitta ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Annexin; Arachidonic acid; Ceramides; Cholesterol; Docosahexaenoic acid

Indexed keywords

ANNEXIN; ARACHIDONIC ACID; CERAMIDE; CHOLESTEROL; DEXAMETHASONE; DOCOSAHEXAENOIC ACID; FATTY ACID; INTRALIPID; LINOLEIC ACID; LIPID; MEMBRANE PHOSPHOLIPID; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; TRANSMEMBRANE CONDUCTANCE REGULATOR; VEGETABLE OIL;

ARTICLE; BACTERIAL COLONIZATION; CELL DIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; CHOLESTEROL METABOLISM; CHRONIC INFLAMMATION; CYSTIC FIBROSIS; ESSENTIAL FATTY ACID DEFICIENCY; FATTY ACID METABOLISM; FATTY ACID SYNTHESIS; HUMAN; LIPID METABOLISM; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SYMPTOM;

ANIMALS; ANNEXINS; ARACHIDONIC ACID; CERAMIDES; CYSTIC FIBROSIS; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS; HUMANS; LINOLEIC ACID; LIPID METABOLISM; MODELS, BIOLOGICAL;

EID: 77956492443     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2010.07.002     Document Type: Article

References (131)

1. Fanconi G., Uehlinger E., Knauer C. Das Coelikisyndrom bie angeboren zystischer Pancreafibromatose und Bronchiektasien. Wien. Med. Wochenschr. 1936, 86:753-756.
2. Andersen D. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study. Am. J. Dis. Child. 1938, 56:344-399.
3. Kuo P.T., Huang N.N., Bassett D.R. The fatty acid composition of the serum chylomicrons and adipose tissue of children with cystic fibrosis of the pancreas. J. Pediatr. 1962, 60:394-403.
4. Underwood B.A., Denning C.R., Navab M. Polyunsaturated fatty acids and tocopherol levels in patients with cystic fibrosis. Ann. NY Acad. Sci. 1972, 203:237-247.
5. Elliott R.B., Robinson P.G. Unusual clinical course in a child with cystic fibrosis treated with fat emulsion. Arch. Dis. Child 1975, 50:76-78.
6. Elliott R.B. A therapeutic trial of fatty acid supplementation in cystic fibrosis. Pediatrics 1976, 57:474-479.
7. Kusoffsky E., Strandvik B., Troell S. Prospective study of fatty acid supplementation over 3 years in patients with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 1983, 2:434-438.
8. Lloyd-Still J., Johnson SB., Holman RT. Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation. Am. J. Clin. Nutr. 1981, 34:1-7.
9. Craig-Schmidt M.C., Faircloth S.A., Teer P.A., Weete J.D., Wu C.Y. The essential fatty acid deficient chicken as a model for cystic fibrosis. Am. J. Clin. Nutr. 1986, 44:816-824.
10. Mischler E., Parrell SW., Farrell PM., Raynor WJ., Lemen RJ. Correction of linoleic acid deficiency in cystic fibrosis. Pedatr. Res. 1986, 20:36-41.
11. van Egmond A.W., Kosorok M.R., Koscik R., Laxova A., Farrell P.M. Effect of linoleic acid intake on growth of infants with cystic fibrosis. Am. J. Clin. Nutr. 1996, 63:746-752.
12. Strandvik B., Hultcrantz R. Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis. Liver 1994, 14:32-36.
13. Strandvik B., Berg U., Kallner A., Kusoffsky E. Effect on renal function of essential fatty acid supplementation in cystic fibrosis. J. Pediatr. 1989, 115:242-250.
14. Strandvik B., Bronnegard M., Gilljam H., Carlstedt-Duke J. Relation between defective regulation of arachidonic acid release and symptoms in cystic fibrosis. Scand. J. Gastroenterol. Suppl. 1988, 143:1-4.
15. Strandvik B. Relation between essential fatty acid metabolism and gastrointestinal symptoms in cystic fibrosis. Acta Paediatr. Scand. Suppl. 1989, 363:58-63. discussion 63-55.
16. Hjelte L., Ahren B., Andren-Sandberg A., Bottcher G., Strandvik B. Pancreatic function in the essential fatty acid deficient rat. Metabolism 1990, 39:871-875.
17. Hjelte L., Larsson M., Alvestrand A., Malmborg A.S., Strandvik B. Renal function in rats with essential fatty acid deficiency. Clin. Sci. (Lond.) 1990, 79:299-305.
18. Freedman S.D., Katz M.H., Parker E.M., Laposata M., Urman M.Y., Alvarez J.G. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proc. Natl. Acad. Sci. USA 1999, 96:13995-14000.
19. Freedman S.D., Weinstein D., Blanco P.G., et al. Characterization of LPS-induced lung inflammation in cftr-/- mice and the effect of docosahexaenoic acid. J. Appl. Physiol. 2002, 92:2169-2176.
20. Freedman S.D., Blanco P.G., Zaman M.M., et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med. 2004, 350:560-569.
21. Lloyd-Still J.D., Powers C.A., Hoffman D.R., et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition 2006, 22:36-46.
22. McKarney C., Everard M., N'Diaye T. Omega-3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database Syst. Rev. 2007, 4:CD002201.
23. Coste T.C., Armand M., Lebacq J., Lebecque P., Wallemacq P., Leal T. An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clin. Biochem. 2007, 40:511-520.
24. De Vizia B., Raia V., Spano C., Pavlidis C., Coruzzo A., Alessio M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. J. Parenter. Enteral. Nutr. 2003, 27:52-57.
25. Durieu I., Vericel E., Guichardant D., et al. Fatty acids platelets and oxidative markers following intravenous n-3 fatty acids administration in cystic fibrosis: an open pilot observational study. J. Cyst. Fibros. 2007, 6:320-326.
26. Buscher R., Grasemann H. Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?. Naunyn Schmiedebergs Arch. Pharmacol. 2006, 374:65-77.
27. Sun F., Mi Z., Condliffe S.B., et al. Chaperone displacement from mutant cystic fibrosis transmembrane conductance regulator restores its function in human airway epithelia. FASEB J. 2008, 22:3255-3263.
28. Bordoni A., Di Nunzio M., Danesi F., Biagi P.L. Polyunsaturated fatty acids: from diet to binding to ppars and other nuclear receptors. Genes Nutr. 2006, 1:95-106.
29. Eyster K.M. The membrane and lipids as integral participants in signal transduction: lipid signal transduction for the non-lipid biochemist. Adv. Physiol. Educ. 2007, 31:5-16.
30. Boland L.M., Drzewiecki M.M. Polyunsaturated fatty acid modulation of voltage-gated ion channels. Cell Biochem. Biophys. 2008, 52:59-84.
31. Schmitz G., Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog. Lipid Res. 2008, 47:147-155.
32. Carlstedt-Duke J., Bronnegard M., Strandvik B. Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc. Natl. Acad. Sci USA 1986, 83:9202-9206.
33. Strandvik B. Nutritional management of cystic fibrosis. Ann. Nestlé 1991, 49:38-46.
34. Gronowitz E., Mellström D., Strandvik B. Normal annual increase of bone mineral density during two years in patients with cystic fibrosis. Pediatrics 2004, 114:435-442.
35. Sahlberg M., Eriksson B.O., Sixt R., Strandvik B. Cardiopulmonary data in response to 6 months of training in physically active adult patients with classic cystic fibrosis. Respiration 2008, 76:413-420.
36. Lannefors L., Lindgren A. Demographic transition of the Swedish cystic fibrosis community-results of modern care. Respir. Med. 2002, 96:681-685.
37. Lepage G., Yesair D.W., Ronco N., et al. Effect of an organized lipid matrix on lipid absorption and clinical outcomes in patients with cystic fibrosis. J. Pediatr. 2002, 141:178-185.
38. Lloyd-Still J.D., Bibus D.M., Powers C.A., Johnson S.B., Holman R.T. Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis. Acta Paediatr. 1996, 85:1426-1432.
39. Maqbool A., Schall J.I., Garcia-Espana J.F., Zemel B.S., Strandvik B., Stallings V.A. Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 2008, 47:635-644.
40. Shoff S.M., Ahn H.Y., Davis L., Lai H. Temporal associations among energy intake, plasma linoleic acid, and growth improvement in response to treatment initiation after diagnosis of cystic fibrosis. Pediatrics 2006, 117:391-400.
41. Tournoud M., Ecochard R., Iwaz J., Steghens J.P., Bellon G., Durieu I. Structural equations to model relationships between pulmonary function, fatty acids and oxidation in cystic fibrosis. Scand. J. Clin. Lab. Invest. 2009, 69:36-44.
42. Armstrong D.S., Hook S.M., Jamsen K.M., et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr. Pulmonol. 2005, 40:500-510.
43. Bruzzese E., Raia V., Gaudiello G., et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol. Ther. 2004, 20:813-819.
44. Norkina O., Kaur S., Ziemer D., De Lisle RC. Inflammation of the cystic fibrosis mouse small intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286:1032-1041.
45. Medjane S., Raymond B., Wu Y., Touqui L. Impact of CFTR DeltaF508 mutation on prostaglandin E2 production and type IIA phospholipase A2 expression by pulmonary epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2005, 289:816-824.
46. Gilljam H., Strandvik B., Ellin A., Wiman L.G. Increased mole fraction of arachidonic acid in bronchial phospholipids in patients with cystic fibrosis. Scand. J. Clin. Lab. Invest. 1986, 46:511-518.
47. Laszlo A., Nemeth M., Gyukovits K. Activity of phospholipase A in serum from patients with cystic fibrosis. Clin. Chim. Acta 1993, 214:105-107.
48. Konstan M.W., Walenga R.W., Hilliard K.A., Hilliard J.B. Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am. Rev. Respir. Dis. 1993, 148:896-901.
49. Reid D.W., Misso N., Aggarwal S., Thompson P.J., Walters E.H. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis. Respirology 2007, 12:63-69.
50. Strandvik B., Svensson E., Seyberth H.W. Prostanoid biosynthesis in patients with cystic fibrosis. Prostaglandins Leukot. Essent. Fatty Acids 1996, 55:419-425.
51. De Lisle R., Meldi L., Flynn M., Jansson K. Altered eicosanoid metabolism in the cystic fibrosis mouse small intestine. J. Pediatr. Gastroenterol. Nutr. 2008, 47:406-416.
52. Levistre R., Lemnaouar M., Rybkine T., Bereziat G., Masliah J. Increase of bradykinin-stimulated arachidonic acid release in a delta F508 cystic fibrosis epithelial cell line. Biochim. Biophys. Acta 1993, 1181:233-239.
53. Berguerand M., Klapisz E., Thomas G., et al. Differential stimulation of cytosolic phospholipase A2 by bradykinin in human cystic fibrosis cell lines. Am. J. Respir. Cell Mol. Biol. 1997, 17:481-490.
54. 2+-induced arachidonic acid release by epithelial cells. DNA Cell Biol. 1997, 16:749-759.
55. Bhura-Bandali F.N., Suh M., Man S.F., Clandinin M.T. The deltaF508 mutation in the cystic fibrosis transmembrane conductance regulator alters control of essential fatty acid utilization in epithelial cells. J. Nutr. 2000, 130:2870-2875.
56. Ollero M., Laposata M., Zaman M.M., et al. Evidence of increased flux to n-6 docosapentaenoic acid in phospholipids of pancreas from cftr-/- knockout mice. Metabolism 2006, 55:1192-1200.
57. Al-Turkmani M.R., Andersson C., Alturkmani R., et al. A mechanism accounting for the low cellular level of linoleic acid in cystic fibrosis and its reversal by DHA. J. Lipid Res. 2008, 49:1946-1954.
58. Kang J.X., Man S.F., Brown N.E., Labrecque P.A., Clandinin M.T. The chloride channel blocker anthracene 9-carboxylate inhibits fatty acid incorporation into phospholipid in cultured human airway epithelial cells. Biochem. J. 1992, 285:725-729.
59. Rogiers V., Dab I., Michotte Y., Vercruysse A., Crokaert R., Vis H.L. Abnormal fatty acid turnover in the phospholipids of the red blood cell membranes of cystic fibrosis patients (in vitro study). Pediatr. Res. 1984, 18:704-709.
60. Zhou J.J., Linsdell P. Molecular mechanism of arachidonic acid inhibition of the CFTR chloride channel. Eur. J. Pharmacol. 2007, 563:88-91.
61. Eidelman O., BarNoy S., Razin M., et al. Role for phospholipid interactions in the trafficking defect of Delta F508-CFTR. Biochemistry 2002, 41:11161-11170.
62. Ulane M.M., Butler J.D., Peri A., Miele L., Ulane R.E., Hubbard V.S. Cystic fibrosis and phosphatidylcholine biosynthesis. Clin. Chim. Acta 1994, 230:109-116.
63. Malavolta M., Bocci F., Boselli E., Frega N.G. Normal phase liquid chromatography-electrospray ionization tandem mass spectrometry analysis of phospholipid molecular species in blood mononuclear cells: application to cystic fibrosis. J. Chromatogr. B Analyt. Technol. Biomed Life Sci. 2004, 810:173-186.
64. Dombrowsky H., Clark G.T., Rau G.A., Bernhard W., Postle A.D. Molecular species compositions of lung and pancreas phospholipids in the cftr(tm1HGU/tm1HGU) cystic fibrosis mouse. Pediatr. Res. 2003, 53:447-454.
65. Linsdell P., Hanrahan J.W. Glutathione permeability of CFTR. Am. J. Physiol. 1998, 275:323-326.
66. Innis S.M., Davidson A.G. Cystic fibrosis and nutrition: linking phospholipids and essential fatty acids with thiol metabolism. Annu. Rev. Nutr. 2008, 28:55-72.
67. Scambi C., Guarini P., De Franceschi L., Bambara L. M. Can 5-methyltetrahydrofolate modify the phospholipid fatty acid pattern in cystic fibrosis pediatric patients?. J. Cyst. Fibros. 2006, 5:197-199.
68. Scambi C., De Franceschi L., Guarini P., et al. Preliminary evidence for cell membrane amelioration in children with cystic fibrosis by 5-MTHF and vitamin B12 supplementation: a single arm trial. PLoS One 2009, 4:e4782.
69. Innis S.M., Davidson A.G., Melynk S., James S.J. Choline-related supplements improve abnormal plasma methionine-homocysteine metabolites and glutathione status in children with cystic fibrosis. Am. J. Clin. Nutr. 2007, 85:702-708.
70. Wegmann M., Nusing R.M. Prostaglandin E2 stimulates sodium reabsorption in MDCK C7 cells, a renal collecting duct principal cell model. Prostaglandins Leukot. Essent. Fatty Acids 2003, 69:315-322.
71. Wang S., Meng F., Xu J., Gu Y. Effects of lipids on ENaC activity in cultured mouse cortical collecting duct cells. J. Membr. Biol. 2009, 227:77-85.
72. Stenvinkel P., Hjelte L., Alvan G., Hedman A., Hultman E., Strandvik B. Decreased renal clearance of sodium in cystic fibrosis. Acta Paediatr. Scand. 1991, 80:194-198.
73. Berdiev B.K., Qadri Y.J., Benos D.J. Assessment of the CFTR and ENaC association. Mol. Biosyst. 2009, 5:123-127.
74. Sigstrom L., Strandvik B. Erythrocyte sodium-potassium transport in cystic fibrosis. Pediatr. Res. 1992, 31:425-427.
75. Clark S., Dunlop M. Modulation of phospholipase A2 activity by epidermal growth factor (EGF) in CHO cells transfected with human EGF receptor. Role of receptor cytoplasmic subdomain. Biochem. J. 1991, 274:715-721.
76. Bensalem N., Ventura A.P., Vallee B., et al. Down-regulation of the anti-inflammatory protein annexin A1 in cystic fibrosis knock-out mice and patients. Mol. Cell Proteom. 2005, 4:1591-1601.
77. Lim L.H., Pervaiz S. Annexin 1: the new face of an old molecule. FASEB J. 2007, 21:968-975.
78. Brennan S. Innate immune activation and cystic fibrosis. Paediatr. Respir. Rev. 2008, 9:271-279. quiz 279-280.
79. Kim S., Ko J., Kim J.H., Choi E.C., Na D.S. Differential effects of annexins I, II, III, and V on cytosolic phospholipase A2 activity: specific interaction model. FEBS Lett 2001, 489:243-248.
80. Monastyrskaya K., Babiychuk E.B., Draeger A. The annexins: spatial and temporal coordination of signaling events during cellular stress. Cell Mol. Life Sci. 2009, 66:2623-2642.
81. Chap H., Fauvel J., Gassama-Diagne A., Ragab-Thomas J., Simon M-F. Une homologie frappante entre le CFTR et les annexines. Médicine/Science 1991, 7:8-9.
82. Trouve P., Le Drevo M.A., Kerbiriou M., et al. Annexin V is directly involved in cystic fibrosis transmembrane conductance regulator's chloride channel function. Biochim. Biophys. Acta 2007, 1772:1121-1133.
83. Le Drevo M.A., Benz N., Kerbiriou M., et al. Annexin A5 increases the cell surface expression and the chloride channel function of the DeltaF508-cystic fibrosis transmembrane regulator. Biochim. Biophys. Acta 2008, 1782:605-614.
84. Della Gaspera B., Weinman S., Huber C., et al. Overexpression of annexin V in cystic fibrosis epithelial cells from fetal trachea. Exp. Cell Res. 1995, 219:379-383.
85. Borthwick L.A., McGaw J., Conner G., et al. The formation of the cAMP/protein kinase A-dependent annexin 2-S100A10 complex with cystic fibrosis conductance regulator protein (CFTR) regulates CFTR channel function. Mol. Biol. Cell 2007, 18:3388-3397.
86. Wainwright B., Farrall M., Watson E., Williamson R. A model system for the analysis of gene exclusion: cystic fibrosis and chromosome 19. J. Med. Genet. 1986, 23:417-420.
87. Strandvik B., Gronowitz E., Enlund F., Martinsson T., Wahlstrom J. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J. Pediatr. 2001, 139:650-655.
88. Aldamiz-Echevarria L., Prieto J.A., Andrade F., et al. Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy. Pediatr. Res. 2009, 66:585-589.
89. Farrell P.M., Mischler E.H., Engle M.J., Brown D.J., Lau S.M. Fatty acid abnormalities in cystic fibrosis. Pediatr. Res. 1985, 19:104-109.
90. Jumpsen J.A., Brown N.E., Thomson A.B., et al. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. J. Cyst. Fibros. 2006, 5:77-84.
91. Van Biervliet S., Devos M., Delhaye T., Van Biervliet J.P., Robberecht E., Christophe A., Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. Prostaglandins Leukot. Essent. Fatty Acids 2008, 78:109-115.
92. Al-Turkmani M.R., Freedman S.D., Laposata M. Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. Prostaglandins Leukot. Essent. Fatty Acids 2007, 77:309-318.
93. Cawood A.L., Carroll M.P., Wootton S.A., Calder P.C. Is there a case for n-3 fatty acid supplementation in cystic fibrosis?. Curr. Opin. Clin. Nutr. Metab. Care 2005, 8:153-159.
94. Beharry S., Ackerley C., Corey M., et al. Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G839-848.
95. Zhang W., Long Y., Zhang J., Wang C. Modulatory effects of EPA and DHA on proliferation and apoptosis of pancreatic cancer cells. J. Huazhong Univ. Sci. Technol. 2007, 27:547-550.
96. Mebarek S., Ermak N., Benzaria A., et al. Effects of increasing docosahexaenoic acid intake in human healthy volunteers on lymphocyte activation and monocyte apoptosis. Br. J. Nutr. 2009, 101:852-858.
97. White N.M., Jiang D., Burgess J.D., Bederman I.R., Previs S.F., Kelley T.J. Altered cholesterol homeostasis in cultured and in vivo models of cystic fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 2007, 292:L476-486.
98. Wassall S.R., Stillwell W. Polyunsaturated fatty acid-cholesterol interactions: domain formation in membranes. Biochim. Biophys. Acta 2009, 1788:24-32.
99. Wang D., Wang W., Duan Y., Sun Y., Wang Y., Huang P. Functional coupling of Gs and CFTR is independent of their association with lipid rafts in epithelial cells. Pflugers Arch. 2008, 456:929-938.
100. Dudez T., Borot F., Huang S., et al. CFTR in a lipid raft-TNFR1 complex modulates gap junctional intercellular communication and IL-8 secretion. Biochim. Biophys. Acta 2008, 1783:779-788.
101. Watkins S.M., Zhu X., Zeisel S.H. Phosphatidylethanolamine-N-methyltransferase activity and dietary choline regulate liver-plasma lipid flux and essential fatty acid metabolism in mice. J. Nutr. 2003, 133:3386-3391.
102. Lasserre M., Mendy F., Spielmann D., Jacotot B. Effects of different dietary intake of essential fatty acids on C20:3 omega 6 and C20:4 omega 6 serum levels in human adults. Lipids 1985, 20:227-233.
103. Cho H.P., Nakamura M.T., Clarke S.D. Cloning, expression, and nutritional regulation of the mammalian Delta-6 desaturase. J. Biol. Chem. 1999, 274:471-477.
104. Vilela R.M., Lands L.C., Meehan B., Kubow S. Inhibition of IL-8 release from CFTR-deficient lung epithelial cells following pre-treatment with fenretinide. Int. Immunopharmacol. 2006, 6:1651-1664.
105. Guilbault C., De Sanctis J.B., Wojewodka G., et al. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 2008, 38:47-56.
106. Guilbault C., Wojewodka G., Saeed Z., et al. Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am. J. Respir. Cell Mol. Biol. 2009, 41:100-106.
107. Noe J., Petrusca D., Rush N., et al. CFTR regulation of intracellular pH and ceramides is required for lung endothelial cell apoptosis. Am. J. Respir. Cell Mol. Biol. 2009, 41:314-323.
108. Boujaoude L.C., Bradshaw-Wilder C., Mao C., et al. Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid. J. Biol. Chem 2001, 276:35258-35264.
109. Teichgraber V., Ulrich M., Endlich N., et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat. Med. 2008, 14:382-391.
110. Hamai H., Keyserman F., Quittell L.M., Worgall T.S. Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling. J. Lipid Res. 2009, 50:1101-1108.
111. Saeed Z., Guilbault C., De Sanctis J.B., et al. Fenretinide prevents the development of osteoporosis in Cftr-KO mice. J. Cyst. Fibros. 2008, 7:222-230.
112. Gronowitz E., Mellström D., Strandvik B. Serum phopholipid fatty acid pattern is associated with bone mineral density in children but not in adults wtih cystic fibrosis. Br. J. Nutr. 2006, 95:1159-1165.
113. Gronowitz E., Lorentzon M., Ohlsson C., Mellström D., Strandvik B. Docosahexaenoic acid is associated with endosteal circumference in long bones in young males with cystic fibrosis. Br. J. Nutr. 2008, 99:160-167.
114. Schroeder T.H., Reiniger N., Meluleni G., Grout M., Coleman F.T., Pier G.B. Transgenic cystic fibrosis mice exhibit reduced early clearance of Pseudomonas aeruginosa from the respiratory tract. J. Immunol. 2001, 166:7410-7418.
115. Grassme H., Jendrossek V., Riehle A., et al. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat. Med. 2003, 9:322-330.
116. Gomez-Munoz A. Ceramide 1-phosphate/ceramide, a switch between life and death. Biochim. Biophys. Acta 2006, 1758:2049-2056.
117. Hannun Y.A., Obeid L.M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Mol. Cell Biol. 2008, 9:139-150.
118. Lamour N.F., Chalfant C.E. Ceramide-1-phosphate: the "missing" link in eicosanoid biosynthesis and inflammation. Mol. Interv. 2005, 5:358-367.
119. Mitsutake S., Igarashi Y. Calmodulin is involved in the Ca2+-dependent activation of ceramide kinase as a calcium sensor. J. Biol. Chem. 2005, 280:40436-40441.
120. Chalfant C.E., Spiegel S. Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J. Cell Sci. 2005, 118:4605-4612.
121. Zhang Y., Li X, Becker K.A., Gulbins E. Ceramide-enriched membrane domains-structure and function. Biochim. Biophys. Acta 2009, 1788:178-183.
122. Goni FM., Alonso A. Effects of ceramide and other simple sphingolipids on membrane lateral structure. Biochim. Biophys. Acta 2009, 1788:169-177.
123. Gentzsch M., Choudhury A., Chang X.B., Pagano R.E., Riordan J.R. Misassembled mutant deltaF508 CFTR in the distal secretory pathway alters cellular lipid trafficking. J. Cell Sci. 2007, 120:447-455.
124. Iuliano L., Monticolo R., Straface G., et al. Association of cholesterol oxidation and abnormalities in fatty acid metabolism in cystic fibrosis. Am. J. Clin. Nutr. 2009, 90:477-484.
125. Brown R.K., Kelly F.J. Role of free radicals in the pathogenesis of cystic fibrosis. Thorax 1994, 49:738-742.
126. 2 and inflammatory cytokine production. PLoS One 2008, 3:e3367.
127. Wood L.G., Fitzgerald D.A., Gibson P.G., Cooper D.M., Garg M.L. Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis patients. Am. J. Clin. Nutr. 2002, 75:668-675.
128. Ng Y., Barhoumi R., Tjalkens R.B., et al. The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and apoptosis in colonocytes. Carcinogenesis 2005, 26:1914-1921.
129. Velsor L.W., Kariya C., Kachadourian R., Day B.J. Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am. J. Respir. Cell Mol. Biol. 2006, 35:579-586.
130. Meves H. Arachidonic acid and ion channels: an update. Br. J. Pharmacol. 2008, 155:4-16.
131. Bootman M.D., Collins T.J., Peppiatt C.M., et al. Calcium signalling-an overview. Semin. Cell Dev. Biol. 2001, 12:3-10.